These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33296560)

  • 1. Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease.
    Nordanstig J; James S; Andersson M; Andersson M; Danielsson P; Gillgren P; Delle M; Engström J; Fransson T; Hamoud M; Hilbertson A; Johansson P; Karlsson L; Kragsterman B; Lindgren H; Ludwigs K; Mellander S; Nyman N; Renlund H; Sigvant B; Skoog P; Starck J; Tegler G; Toivola A; Truedson M; Wahlgren CM; Wallinder J; Öjersjö A; Falkenberg M
    N Engl J Med; 2020 Dec; 383(26):2538-2546. PubMed ID: 33296560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial.
    Barco S; Sebastian T; Voci D; Engelberger RP; Grigorean A; Holy E; Leeger C; Münger M; Périard D; Probst E; Spescha R; Held U; Kucher N
    Trials; 2022 Apr; 23(1):334. PubMed ID: 35449070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Term Outcomes After Revascularisations Below the Knee with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
    Heidemann F; Peters F; Kuchenbecker J; Kreutzburg T; Sedrakyan A; Marschall U; L'Hoest H; Debus ES; Behrendt CA
    Eur J Vasc Endovasc Surg; 2020 Oct; 60(4):549-558. PubMed ID: 32807674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality Following Treatment With and Without Paclitaxel-Coated Devices in Dialysis Patients.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Hofmann V; Nührenberg T; Neumann FJ; Zeller T
    J Endovasc Ther; 2024 Apr; 31(2):248-256. PubMed ID: 36052426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
    Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
    J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Limmer AM; Chen AZL; Thomas SD; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2021 Oct; 28(5):755-777. PubMed ID: 34106028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
    Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
    Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-Year Paclitaxel Dose-Related Outcomes of Drug-Eluting Stents Treated Below the Knee in Patients with Chronic Limb-Threatening Ischemia (The PADI Trial).
    Konijn LCD; Wakkie T; Spreen MI; de Jong PA; van Dijk LC; Wever JJ; Veger HTC; Statius van Eps RG; Mali WPTM; van Overhagen H
    Cardiovasc Intervent Radiol; 2020 Dec; 43(12):1881-1888. PubMed ID: 32725411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
    Behrendt CA; Sedrakyan A; Peters F; Kreutzburg T; Schermerhorn M; Bertges DJ; Larena-Avellaneda A; L'Hoest H; Kölbel T; Debus ES
    Eur J Vasc Endovasc Surg; 2020 Apr; 59(4):587-596. PubMed ID: 31926836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
    Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Rosenfield K; Jaff MR; White CJ; Rocha-Singh K; Mena-Hurtado C; Metzger DC; Brodmann M; Pilger E; Zeller T; Krishnan P; Gammon R; Müller-Hülsbeck S; Nehler MR; Benenati JF; Scheinert D;
    N Engl J Med; 2015 Jul; 373(2):145-53. PubMed ID: 26106946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
    Micari A; Brodmann M; Keirse K; Peeters P; Tepe G; Frost M; Wang H; Zeller T;
    JACC Cardiovasc Interv; 2018 May; 11(10):945-953. PubMed ID: 29798770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
    Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
    J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
    Beckman JA; White CJ
    Circulation; 2019 Oct; 140(16):1342-1351. PubMed ID: 31177820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.